InsidersTradesSigma
Track the 之江生物 stock price and the full management transaction log of the company, a publicly traded company based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 之江生物 has recorded 5 insider filings. Market capitalisation: €3bn. The latest transaction was filed on 5 February 2024 (Purchase). Among the most active insiders: 邵俊斌. All data is free.
5
Insider Decl.
n/a
Thresholds
€342,152
5 ops.
Buy Volume
n/a
n/a
Sell Volume
10Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,713 of 29,063 companies
34.7
score / 100
Value40
Quality30
FCF yld2.2%
Earn yld-1.1%
EV/EBITDA·
ROE-1.3%
Gross mgn64%
Net mgn-27%
Debt/EBITDA10.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 February 2024
Declarations5 total
5 of 5 declarations
关于 之江生物
之江生物是一家专注于医疗保健和制药领域的公司，在 XSHG 市场上市。它致力于开发创新的生物解决方案。